hgh injections: Frequently asked questions

HGH is the more practical tool for chronic elevation studies. Daily HGH injections at 0.1–0.2 IU/kg maintain stable serum IGF-1 levels between 300–500 ng/mL (depending on baseline and dose) without excessive peak-trough variation. IGF-1 LR3 can achieve the same outcome but requires more frequent dose adjustments because its receptor occupancy is immediate and dose-proportional. Small dosing errors create larger fluctuations in tissue-level signaling. HGH's hepatic synthesis buffer smooths variability.

Use HGH instead of IGF-1 LR3. HGH's diabetogenic effect (via GH receptor-mediated insulin resistance) counteracts its IGF-1-driven glucose uptake, producing net-neutral or slightly elevated fasting glucose in most research models. IGF-1 LR3's pure IGF-1R agonism drives GLUT4 translocation and glucose uptake without the opposing GH receptor effect, increasing hypoglycemia risk at doses above 80 mcg/day. Protocols using IGF-1 LR3 above 100 mcg must monitor glucose every 4–6 hours and provide carbohydrate supplementation if fasting glucose drops below 70 mg/dL.

HGH is the appropriate choice. It engages the full hypothalamic-pituitary-hepatic axis, including negative feedback loops where elevated IGF-1 suppresses further growth hormone secretion. IGF-1 LR3 bypasses these regulatory checkpoints entirely, making it unsuitable for studies investigating endogenous somatotropic control. Research examining metabolic integration, age-related GH decline, or pituitary function requires a compound that operates through physiological pathways, not one engineered to evade them.

IGF-1 LR3 is the only viable option. Inject 40–80 mcg subcutaneously immediately after the experimental stimulus (e.g., resistance exercise, nutrient bolus) and measure mTOR phosphorylation at Ser2448 via Western blot 2–4 hours later. HGH cannot produce meaningful IGF-1 receptor activation within that window. Serum IGF-1 hasn't peaked yet, and tissue-level receptor occupancy lags even further behind. Attempting this protocol with HGH would measure baseline mTOR activity, not stimulus-induced activation.

Switch to IGF-1 LR3 as the primary anabolic peptide. IGF-1 receptors share structural homology with insulin receptors and activate overlapping signaling cascades (PI3K-Akt pathway) that enhance glucose uptake in muscle and adipose tissue. HGH's insulin resistance develops through direct GH-receptor activation in hepatocytes, which opposes insulin signaling and increases hepatic glucose output. LR3 bypasses this pathway entirely. It doesn't engage GH receptors, so the counter-regulatory glucose effect doesn't occur.

Select IGF-1 LR3. It delivers direct receptor binding within hours of administration, with measurable downstream signaling (PI3K/Akt, mTOR activation) detectable within 48–72 hours. HGH's hepatic conversion pathway introduces a 5–7 day lag before endogenous IGF-1 levels rise sufficiently to produce comparable tissue effects. The mechanistic difference is non-negotiable here: if the experimental window is short or the research question specifically concerns IGF-1 receptor pathway dynamics, HGH's indirect mechanism adds a variable (hepatic synthesis rate) that IGF-1 LR3 eliminates.

IGF-1 LR3's reduced IGFBP affinity means most circulating compound remains unbound, simplifying assay interpretation. Native IGF-1 exists primarily in the IGFBP-3/ALS ternary complex, requiring dissociation before receptor binding. Free IGF-1 represents less than 1% of total circulating IGF-1. IGF-1 LR3 avoids this complexity because the structural modifications prevent binding protein sequestration, though standard IGF-1 immunoassays may not distinguish between native IGF-1 and the LR3 analogue without specific antibody selection.

IGF-1 LR3 shows initial concentration at injection sites with gradual systemic redistribution over 12–18 hours. Radiolabeled tracer studies demonstrated peak muscle tissue concentration within 90 minutes post-injection, followed by declining local levels as the compound enters circulation. HGH cannot achieve localized effects. Its mechanism depends on systemic hepatic IGF-1 release, making tissue-specific targeting impossible.

Reduce the dose or administer with carbohydrate co-ingestion. IGF-1 receptor activation increases GLUT4 translocation in muscle cells, lowering blood glucose more aggressively than HGH. Hypoglycemic episodes typically occur at doses above 80 mcg daily or when administered fasted. Our team has found that splitting the dose into 40 mcg twice daily with meals stabilizes glucose levels while maintaining anabolic signaling.

It does. But the risk profile changes. HGH stimulates hepatic IGF-1 production, and exogenous LR3 adds direct receptor activation on top of that endogenous synthesis. The cumulative IGF-1 receptor load can produce pronounced hypoglycemia, edema, or joint pain if dosing isn't carefully titrated. Protocols combining both peptides typically reduce each individual dose by 40–50% compared to monotherapy. For example, 2 IU HGH plus 30 mcg LR3 rather than 4 IU HGH or 60 mcg LR3 alone.

IGF-1 LR3 bypasses hepatic synthesis entirely. It activates receptors directly regardless of liver function. HGH requires functional hepatocytes to produce IGF-1 via JAK2/STAT5 signaling; liver disease, malnutrition, or insulin resistance all impair this conversion. Animal models with induced hepatic dysfunction show preserved IGF-1 receptor response to exogenous IGF-1 LR3 but blunted response to HGH administration.

Use IGF-1 LR3 with dosing every 24–48 hours. The 20–30 hour half-life maintains plasma concentrations above baseline for extended periods, eliminating the trough effect seen with HGH's 3–4 hour half-life. Studies requiring consistent receptor occupancy without frequent intervention benefit from IGF-1 LR3's pharmacokinetic profile, though researchers must account for the extended clearance time when designing washout periods.

IGF-1 LR3's reduced IGFBP affinity makes it the compound of choice when binding protein sequestration would obscure receptor-level effects. Native IGF-1 and HGH-stimulated endogenous IGF-1 both circulate predominantly bound to IGFBP-3, meaning only 1–2% exists in free form at any given moment. If the research question concerns receptor occupancy kinetics or requires sustained free peptide availability, IGF-1 LR3's structural modifications eliminate the binding protein variable. Protocols studying IGFBP regulation itself would conversely require native IGF-1 or HGH to preserve that interaction.

Use exogenous HGH. MK-677 cannot achieve IGF-1 elevations above ~90% baseline even at supraphysiological doses (50mg daily). HGH injections at 4–6 IU daily reliably produce IGF-1 levels 150–250% above baseline, which may be necessary for specific anabolic or metabolic research endpoints. The trade-off is complete pituitary suppression and 30–60 day recovery timeline, but if the research question demands that level of IGF-1 saturation, secretagogues won't deliver it.

Choose MK-677. It's the only option that doesn't suppress your pituitary. Ghrelin receptor agonism amplifies endogenous secretion without triggering negative feedback, so your natural GH axis remains intact. HGH injections shut down pituitary function within weeks. Restarting natural production after cessation can take months and often requires peptide protocols (GHRP-2, CJC-1295) to re-sensitize the axis. If preserving endogenous capacity matters, MK-677 is non-negotiable.

MK-677 eliminates that variable entirely. It's orally bioavailable and requires only once-daily dosing. For long-duration studies (6+ months) or models where daily subcutaneous injections introduce logistical complexity, MK-677 provides consistent GH elevation without the injection burden. HGH requires cold storage, reconstitution, sterile technique, and daily adherence. Any protocol disruption creates gaps in dosing that MK-677's 24-hour receptor occupancy doesn't experience.

MK-677 is the only option. Studies examining circadian rhythm effects, sleep architecture changes, or metabolic responses dependent on pulsatile GH signaling cannot use exogenous HGH. It flattens the pulse pattern entirely. MK-677 preserves the natural 6–8 daily pulses, allowing observation of how amplified endogenous secretion (rather than replacement) affects downstream outcomes. This is particularly relevant in aging research, where restoring youthful pulse amplitude without suppressing the axis is the therapeutic goal.

HGH injections deliver higher IGF-1 levels, period. At 4–6 IU/day, you can reach 300–400% above baseline. Something MK-677 simply cannot achieve. The trade-off is complete suppression of natural secretion and the need for daily injections. If the research endpoint requires supraphysiological IGF-1 and the duration is limited (8–12 weeks), HGH is the mechanistically appropriate choice. Beyond 12 weeks, receptor downregulation becomes a confounding variable.

MK-677 delivers equivalent IGF-1 elevation at a fraction of HGH's cost. Pharmaceutical-grade HGH runs $400–$800 monthly for 2 IU daily dosing, and $1,200–$2,000 monthly at 4–6 IU. Research-grade MK-677 at 25mg daily costs $60–$120 monthly. Over six months, that's $360–$720 for MK-677 versus $2,400–$4,800 for HGH at comparable IGF-1 outcomes. The cost gap widens when you factor in ancillary expenses: HGH requires bacteriostatic water, insulin syringes, and refrigerated storage. If budget dictates the decision and you're targeting mid-range IGF-1 elevation, MK-677 is the economically rational choice.

No. MK-677's IGF-1 elevation is cumulative, not dose-dependent in the short term. Doubling the dose to 50mg daily won't double your IGF-1 response or cut the plateau timeline in half. It primarily increases side effects (water retention, lethargy, appetite surge). The clinical dose-response curve for MK-677 plateaus around 25mg daily; higher doses show diminishing returns. If you need rapid IGF-1 titration within days, HGH injections are the only option that delivers that kinetic profile. MK-677 is a slow-burn compound designed for sustained elevation over weeks to months.